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Summary
Chronic lymphocytic leukemia (CLL) usually follows an indolent course. Yet, pro-
gression into a diffuse large B cell lymphoma (DLBCL) known as Richter’s syn-
drome (RS) occurs in 2-10 % of patients and results in a very poor prognosis. Mu-
tations frequently involved in RS transformation affect TP53, CDKN2A, or c-MYC,
however, a huge proportion of patients do not have acquired additional mutations
and the molecular mechanisms involved still remain unknown. Due to the high
dependence of CLL B cells on B cell receptor (BCR) mediated survival signals, the
influence of a constitutively active AKT (AKT-CA), a pivotal signal molecule of the
BCR, was investigated on a murine CLL background (Eµ-TCL-1) resulting in the
TCA and TC 1A mouse line. Here, we not only define a connection between high-
risk mutations and elevated pAKT levels in CLL patients, but more importantly
show that AKT-CA expressing CLL cells progress to RS in mice. Moreover, a small
population of CLL cells expressing AKT-CA was sufficient to induce RS suggesting
that the subpopulation clonally expands and outcompetes the other CLL cells. In
12.5 % of RS patients elevated AKT activation was identified, supporting the obser-
vation in mice that survival signals in CLL cells can drive disease progression to
RS. The new RS mouse model will help to decipher the molecular mechanisms re-
sponsible for transforming events. Preliminary results show that pAKT likely acts
via GSK-3  inhibition and subsequent c-Myc and/or Mcl-1 stabilization resulting
in increased survival and proliferation. AKT activity is also linked to genomic in-
stability, which in turn leads to further mutations resulting in transforming events
within a cell. To identify new treatments for RS patients with elevated pAKT lev-
els, models such as the TCA and TC 1A mouse lines are essential to test therapies
prior to clinical trials. Moreover, this work supports the use of pAKT staining as a
prognostic tool to identify this subgroup of RS patients and to find the most effec-
tive and tailored treatment including the use of AKT inhibitors. Taken together, this
study unraveled the critical impact of aberrant AKT activation in RS transformation
and provides the first mouse model for Richter’s syndrome.
